IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

Core Insights - IMUNON, Inc. is advancing its pivotal Phase 3 OVATION 3 trial for IMNN-001, a DNA-mediated immunotherapy targeting newly diagnosed advanced ovarian cancer, with a poster presentation accepted at the ESMO Congress 2025 [1][2][5] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments utilizing non-viral DNA technology, specifically the TheraPlas® platform for gene-based delivery of cytokines [11][12] Product Details - IMNN-001 is an IL-12 DNA plasmid vector designed to induce strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression [2][9] - The therapy has shown promising results in the Phase 2 OVATION 2 study, demonstrating a median overall survival increase of 13 months and a median progression-free survival increase of 3 months compared to standard care [6][8] Clinical Trial Information - The OVATION 3 trial is designed with at least 95% statistical power for the primary endpoint of overall survival, with plans for two interim analyses to potentially expedite FDA submission [7] - Currently, four clinical sites are active for patient enrollment, with up to 46 additional sites being considered [3][7] ESMO Conference Presentation - The abstract for the OVATION 3 trial will be presented by Dr. Premal H. Thaker at the ESMO Congress 2025, highlighting the safety and efficacy of IMNN-001 in combination with standard chemotherapy [3][4]